CSL Ltd shares slide as investors weigh growth outlook

CSL Ltd, the Australian biotech giant behind plasma‑derived therapies, vaccines and specialist health products, has seen its share price fall about 27% since the start of 2025. Investors are questioning recent performance issues in divisions such as Vifor and are assessing whether the challenges are temporary setbacks or signal deeper structural problems.

Analysts note that despite the price decline, CSL benefits from long‑term demand for its medical products, a strong dividend yield of roughly 3.15% (above its five‑year average), and a reputation for stable, “sticky” revenue in the healthcare sector. Global healthcare spending, especially in the United States, is projected to grow, offering further growth potential for CSL’s plasma and vaccine businesses. The company's scale and regulatory expertise are seen as barriers to new competition, leading some investors to view the current dip as a buying opportunity.

Overall, the market’s reduced confidence reflects short‑term execution concerns, yet the underlying business fundamentals—including global scale, essential medical products and attractive dividend returns—remain a key focus for Australian investors.